Related Experiment Video
Updated: Apr 22, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia
Lori E Crosby1,2, Lisa M Shook2,3, Russell E Ware2,3,4
1Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Abstract:
Clinical trials have demonstrated hydroxyurea's efficacy in improving health outcomes for children with sickle cell anemia (SCA) who have medical complications. New NHLBI clinical guidelines will recommend offering hydroxyurea to young patients regardless of clinical severity. Shared decision making may be an effective approach for implementing this practice change. Decision aids that help patients/parents feel empowered to make this decision and help providers feel comfortable in discussing hydroxyurea as a preventive treatment may facilitate shared discussions between families and providers. We recommend six strategies providers can use to facilitate these discussions while decision aids and tools are being developed. Pediatr Blood Cancer 2015;62:184-185. © 2014 Wiley Periodicals, Inc.
More Related Videos
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Hemodialysis III: Nursing Management
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Chronic Kidney Disease IV: Nursing Management
Hemodialysis II: Procedure and Complications

